Wells Fargo has initiated coverage on Maze Therapeutics Inc (MAZE) with an Overweight rating. This marks the firm's first assessment of the clinical-stage biopharmaceutical company, which focuses on developing precision medicines for renal, cardiovascular, and related metabolic diseases. The company is headquartered in South San Francisco, California, and employs 125 full-time staff.
Maze Therapeutics, which went public on January 31, 2025, has a market capitalization of $1.4 billion. Its lead programs include MZE829, an oral small-molecule inhibitor targeting apolipoprotein L1 for treating APOL1 kidney disease, and MZE782, aimed at the solute transporter SLC6A19 for chronic kidney disease.
The current stock price stands at $42.95, reflecting the company's ongoing efforts to harness human genetics through its Maze Compass platform, which informs all phases of drug discovery and development.
Analyst ratings, like this one from Wells Fargo, provide insights based on research and financial models, but they should be considered alongside other factors such as company fundamentals and market trends. Ratings can evolve as new information emerges, and different analysts may hold varying opinions on the same company.